ArticleJournal of hepatology2017
Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
Article in Journal of hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 49 citations in OpenAlex.
- Sunitinib induces immunogenic cell death through eIF2α phosphorylation to potentiate immunotherapy in HCC.iScience · 2026Article
- ModulatingJournal for immunotherapy of cancer · 2026Article
- Voacangine targeting of PI3K/Akt/ERK via the knockdown of inflammation in DEN-induced liver cancer: in vivo and in silico approach.Journal of molecular histology · 2025Article
- Immune characteristics associated with lymph node metastasis in early-stage NSCLC.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinoma.Cancer immunology, immunotherapy : CII · 2023Article
- Multifunctional Nanoplatform Based on Sunitinib for Synergistic Phototherapy and Molecular Targeted Therapy of Hepatocellular Carcinoma.Micromachines · 2023Article
- Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma.Frontiers in immunology · 2023Review
- Machine learning integrations for development of a T-cell-tolerance derived signature to improve the clinical outcomes and precision treatment of hepatocellular carcinoma.American journal of cancer research · 2023Article
- Review
- Nanoliposome C6-Ceramide in combination with anti-CTLA4 antibody improves anti-tumor immunity in hepatocellular cancer.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Article
- Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics.Expert opinion on therapeutic targets · 2021Review
- Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades.Molecular cancer · 2021Review
- Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges.Frontiers in cell and developmental biology · 2021Review
- Identification of Gene-Set Signature in Early-Stage Hepatocellular Carcinoma and Relevant Immune Characteristics.Frontiers in oncology · 2021Article
- Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response.Journal for immunotherapy of cancer · 2020Article
- Review
- Anticancer effect of caudatin in diethylnitrosamine‑induced hepatocarcinogenesis in rats.Molecular medicine reports · 2020Article
- CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Current statuses of molecular targeted and immune checkpoint therapies in hepatocellular carcinoma.American journal of cancer research · 2020Article
- Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors.American journal of cancer research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsWe have established a clinically relevant animal model of hepatocellular cancer (HCC) in immune competent mice to elucidate the complex dialog between host immunity and tumors during HCC initiation and progression. Mechanistic findings have been leveraged to develop a clinically feasible anti-tumor chemoimmunotherapeutic strategy.
methodsIntraperitoneal injection of carbon tetrachloride and intrasplenic inoculation of oncogenic hepatocytes were combined to induce progressive HCCs in fibrotic livers of immunocompetent mice. Immunization and adoptive cell transfer (ACT) were used to dissect the tumor antigen-specific immune response. The ability of the tyrosine kinase inhibitor sunitinib to enhance immunotherapy in the setting of HCC was evaluated.
resultsThis new mouse model mimics human HCC and reflects its typical features. Tumor-antigen-specific CD8
conclusionTreg accumulation and upregulation of PD-1 provide two independent mechanisms to induce profound immune tolerance in HCC. Chemoimmunotherapy using Food and Drug Administration-approved sunitinib with anti-PD-1 antibodies achieved significant tumor control, supporting translation of this approach for the treatment of HCC patients. LAY SUMMARY: In the current study, we have established a clinically relevant mouse model which mimics human liver cancer. Using this unique model, we studied the response of the immune system to this aggressive cancer. Findings from this trial have led to the development of an innovative and clinically feasible chemoimmunotherapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.